80% of dementia patients suffer from Alzheimer’s disease
Dementia primarily afflicts older people, but it is not part of normal ageing. Alzheimer’s is the only top killer that cannot be prevented, cured, or even slowed down and it imposes a high cost on society. Addressing the high unmet medical needs in Alzheimer’s disease is therefore a major priority for both publicly funded scientific research and the healthcare industry. Learn more
How big is the problem?
Learn more about Alzheimer’s disease and how Alzinova is addressing the high unmet medical need in this indication. Read more
What is our solution?
Learn more about how Alzinova is using it’s unique proprietary ”AβCC Peptide™ Technology” to develop disease-modifying treatments against Alzheimer’s disease. Read more
Latest press releases
- 2020-11-16 | Regulatory Last day of trading in paid subscription units (Sw.BTU) and first day of trading for TO2 2020/2022
- 2020-11-04 | Regulatory Alzinova AB announces the study design for the first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 at a scientific congress.
Events & presentations
- 2020-11-04 Study design for the first clinical study with the oligomer-specific therapeutic vaccine ALZ-101 presented at Clinical Trials in Alzheimer’s Disease (CTAD) 2020
- 2020-10-15 Redeye Neurology Seminar CNS, October 15, 2020 - webcast presentation (in Swedish)